- Conditions
- Alopecia Areata
- Interventions
- CTP-543
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 937–960
of 2,082
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ABT-089
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 21
- States / cities
- Mesa, Arizona • Lafayette, California • San Diego, California + 17 more
- Conditions
- Solid Tumors
- Interventions
- Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Fort Myers, Florida • Nashville, Tennessee + 1 more
- Conditions
- Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency
- Interventions
- UX007
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Lurasidone HCl
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more
- Conditions
- Generalized Epilepsy
- Interventions
- BHV-7000, Placebo
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Vulvovaginal Atrophy
- Interventions
- WC3011 Estradiol Vaginal Cream
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 64
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- Refractory Generalized Myasthenia Gravis
- Interventions
- Eculizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 22 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- K-877, Fenofibrate, Placebo (for K-877)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 129
- States / cities
- Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
- Conditions
- Major Depressive Disorder
- Interventions
- ALTO-300, Placebo
- Drug
- Lead sponsor
- Alto Neuroscience
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Yuma, Arizona • Rogers, Arkansas + 64 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
- Drug
- Lead sponsor
- Minerva Neurosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Lung Diseases
- Interventions
- Zepatier, Epclusa
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 67 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Interventions
- DCC-2618
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Rett Syndrome
- Interventions
- Trofinetide
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 21 Years · Female only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Arthroplasty
- Interventions
- Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
- Conditions
- Opioid Dependency
- Interventions
- Probuphine (buprenorphine implant)
- Drug
- Lead sponsor
- Titan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Risdiplam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Month to 7 Months
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Tibulizumab Dose A, Tibulizumab Dose B, Placebo
- Biological · Other
- Lead sponsor
- Zura Bio Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
- Conditions
- Colitis, Ulcerative
- Interventions
- GSK2982772, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more
- Conditions
- Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 0 Years to 17 Years
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Memphis, Tennessee + 1 more
- Conditions
- Alzheimer's Disease
- Interventions
- Idalopirdine 60 mg
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
- Conditions
- Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
- Interventions
- Finerenone (Kerendia, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more